What to Ask a GLP-1 Compounding Pharmacy Before Ordering: 16 Questions

By the Weight Loss Provider Guide Research Team · Last verified: August 8, 2026 · Next check: September 2026

Advertising disclosure: We earn affiliate commissions from some links on this page. Which providers we recommend is decided by what we can verify — not by what pays us. Three companies that pay us are deliberately not recommended here, and we say why. Full disclosure →

---

Here is what to ask a GLP-1 compounding pharmacy before ordering: the pharmacy's legal name and state license, who wrote your prescription and why a compounded version instead of an FDA-approved one, the exact drug and every added ingredient, whether it's the base molecule or a salt form, what finished-preparation testing or release checks cover your lot (not just the raw powder), your dose in both milligrams and syringe units, the beyond-use date, the warm-package policy, and every charge you'll see on your card.

Stop and walk away if any one of these is true: nobody will name the pharmacy before your medication charge becomes non-refundable, there's no real medical screening or prescription, the label says semaglutide sodium or acetate, or the seller calls it "generic Wegovy" or "the same as Ozempic." The last three map directly to FDA warnings. The pharmacy-name rule is ours: none of the checks on this page work without a name.

And one thing most guides skip: the answers only work if you ask the right party. Your telehealth company should not be the final source for what's in the vial. The pharmacy can't tell you why your prescriber chose a compound. Ask the wrong person and you'll get a confident answer that isn't worth anything.

Compounded GLP-1s are not FDA-approved. The FDA does not review them for safety, effectiveness, or quality before they're sold. That's not a scare line — it's the reason this page exists. When the usual safety net isn't there, you build your own. Sixteen questions is what that looks like.

Free, no email required: copy the full script, send it in one message, and grade the replies against our answer key below.

Copy the 16-question script →

---

We built this on August 8, 2026 by starting with primary regulatory records. We used independent analysis and company pages only for claims we clearly attribute to those sources:

• FDA, "FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss" (page content current 06/15/2026)
• FDA, "FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize" (April 1, 2026)
• FDA, "Bulk Drug Substances Used in Compounding Under Section 503A"
• FDA, "FDA alerts health care providers, compounders and patients of dosing errors"
• FDA, "FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List" (April 30, 2026), plus Federal Register 91 FR 23431 and the comment-period extension to July 30, 2026
• FDA, Drug Establishments Current Registration Site (DECRS) and the Electronic Drug Registration and Listing System
• Mississippi Board of Pharmacy semaglutide compounding guidance, the New Jersey Board of Pharmacy semaglutide compounding statement, and the Ohio Board of Pharmacy GLP-1 guidance
• Brookings, "The Wild East of semaglutide" (April 21, 2025)
• Eli Lilly, open letter on tirzepatide compounded with vitamin B12 (March 12, 2026), and the Alliance for Pharmacy Compounding's published response
• Stanford Medicine, "Compounded GLP-1s: Why doctors worry and the FDA is cracking down" (July 16, 2026)
• Ro's pricing and insurance pages, Embody's pricing and terms, and Enhance.MD's terms and published GLP-1 page, all checked August 8, 2026

What we did not do: we did not buy, test, or lab-analyze any product. We did not inspect a pharmacy. We did not call any pharmacy for this page. No consumer checklist — ours or anyone else's — can tell you whether one specific vial is sterile, correctly dosed, or right for your body. What this page does is narrower and still worth your time: it shows you exactly what's missing before your money and your medication are committed.

Correction we're making to our own coverage: our earlier compounding guides cited FDA adverse-event totals of 605 for compounded semaglutide and 545 for compounded tirzepatide, current as of July 31, 2025. FDA's page now reports 990 reports for compounded semaglutide and more than 730 for compounded tirzepatide as of May 31, 2026. This page now uses FDA's current figures. Any older guide that still shows 605/545 needs the same correction.

---

Answer capsule: Three different parties hold the answers to a compounded GLP-1 order. Each owns a different set of facts, and none should be treated as the final source for the others. The telehealth company usually controls or communicates pharmacy assignment, pricing, changes, and cancellation. The prescriber owns the medical reason, the prescription, and the dose. The pharmacy owns the formulation, the ingredient records, the testing, the beyond-use date, the label, and shipping. Asking a support chat agent about sterility testing can produce a confident answer that nobody can stand behind.

This is the part almost every checklist online gets wrong, and it's why so many people come away thinking they "asked" and got nowhere.

Picture three desks.

Desk one is the telehealth company. They took your money and built the website. They usually choose from a pharmacy network or tell you where the prescription was sent. They control your price, your renewal date, and your cancel button. They do not make your medicine, so their support team should not be the final source for what's in it.

Desk two is your prescriber. A licensed clinician who reviewed your intake. They own the medical decision: whether a GLP-1 is right for you, why you're being given a compounded version instead of an approved one, and what dose to write. That last one matters more than people realize — the FDA has documented prescribers miscalculating compounded doses, not just patients.

Desk three is the pharmacy. The actual facility that compounded and dispensed your medication. They own the formula, the raw ingredient paperwork, the testing, the date on the label, and how the medication gets to your porch.

Here's the practical move that saves you a week: send one message to the telehealth company and ask them to route each question to the right desk. Say it plainly. "Some of these are for the pharmacy and some are for my prescriber — please forward them and reply in writing." A company that can do that is organized. A company that answers all sixteen from one chat script without routing the questions or naming its source is asking you to trust a script, and that tells you something too.

---

Answer capsule: Send all sixteen questions in one written message before your medication charge goes through, and save the reply. The questions cover pharmacy identity and licensing, the medical reason for compounding, the exact formulation and added ingredients, ingredient and finished-product testing, dose math, beyond-use dating, shipping temperature, recall contact, and total cost. A written answer you can save is worth more than a friendly phone call you can't.

Copy this. Paste it into chat, email, or the patient portal. Don't apologize for asking — you're about to inject something.

Hi — before my medication charge goes through, I'd like a few things in writing for my records. Some of these are for the pharmacy and some are for my prescriber. Could you route them and reply in writing? Thanks.

About the pharmacy

1. What is the legal name, city, and state of the pharmacy that will compound and ship my medication?
2. When will I be told which pharmacy it is — before or after my medication charge is processed?
3. Is it a state-licensed pharmacy operating under Section 503A or an FDA-registered 503B outsourcing facility? What state license number or FDA listing should I use to look it up?
4. Is that pharmacy licensed to ship prescriptions to my state?

About my prescription

5. Who is the licensed clinician prescribing this, and how do I reach a clinician or pharmacist after delivery?
6. If this product would otherwise be an essentially identical copy of an available FDA-approved drug, what change did my prescriber determine makes a significant difference for me, and is that determination documented in my chart?
7. What exactly is being prescribed — drug, dosage form, route, strength, and a complete list of every added ingredient and its amount?
8. If this contains semaglutide, is the active ingredient semaglutide base, or a salt form such as semaglutide sodium or semaglutide acetate?

About what's in the vial

9. Who manufactures the active ingredient, in what country, and is that manufacturer registered with the FDA?
10. Is there a certificate of analysis for the ingredient lot used in my medication? What specification was it tested against, who owns that specification, and which lab ran the test?
11. What testing or release checks apply to the finished preparation — not just the raw ingredient — and what can you share about my lot?
12. What is the concentration in milligrams per milliliter, and how much total medication is in the vial?

About using it safely

13. What is my prescribed dose in milligrams, how many syringe units is that at this concentration, and what syringe size should I use? Will you send it?
14. What is the beyond-use date, how was it set, and will my whole supply be used before that date?
15. What temperature does this need in transit and storage, and what is your written policy if it arrives warm, damaged, or late?

About money and what comes next

16. What is my total charge today and at every renewal, including membership, medication, dose increases, supplies, and shipping — plus the cancellation deadline, refund terms, and how I cancel? Also: can you change my pharmacy or my formula later, and will you tell me before the next fill?

That's the whole thing. It takes about ninety seconds to send.

One quiet benefit nobody mentions: the message itself is a record. If anything ever goes sideways — a billing fight, a changed formula, a chargeback — you'll have a timestamped document of exactly what you were told at signup. That record can matter more than a review written by someone else.

Use the answer key below → No email. Grade every reply before the medication charge becomes non-refundable.

---

Answer capsule: A list of questions is useless if you can't tell a real answer from a rehearsed one. For each of the sixteen questions, a passing answer is specific, written, and checkable against an outside record; a failing answer is a category ("licensed," "FDA-registered," "pharmaceutical grade") with no name, number, or document behind it. Two of the sixteen can be verified in public databases without the seller's cooperation.

This table is the reason this page exists. Everyone gives you questions. Nobody tells you how to grade the reply.

How to score what comes back

Don't overthink this. Six areas, four points each, twenty-four total. We call it a documentation score, and we want to be precise about what it is: it measures how much you were actually told. It is not a safety score, and it cannot tell you whether one vial is good.

21–24: You got most of what you asked for. That's a documented order, not a guaranteed one. 16–20: Send the leftovers back and get them in writing before you authorize the medication. 10–15: Too much is missing to make an informed call. Below 10: You don't have enough to decide. Don't. Any hard stop: the score doesn't matter. See the next section.

---

Answer capsule: Eleven answers should end the conversation. Most come from FDA safety, labeling, licensing, or telehealth warnings. Two are our decision rules: do not let the charge become non-refundable while the pharmacy is hidden, and do not inject when the dose numbers cannot be reconciled. A separate list of things people treat as failures — no optional accreditation, an old inspection observation, a multi-pharmacy network — are reasons to ask one more question, not reasons to leave.

🚫 The eleven hard stops

Any single one of these, and you're done. Not "negotiate." Done.

1. No real screening and no prescription. FDA lists this as a telehealth warning sign.
2. They won't identify the pharmacy before your medication charge is non-refundable. This is our rule, not an FDA rule. You can't verify anything without a name.
3. You cannot verify the pharmacy in your state's board of pharmacy database after checking the exact legal name and asking the board about any mismatch. FDA's guidance is blunt: if an online pharmacy isn't listed, don't use it.
4. Semaglutide sodium or semaglutide acetate. FDA calls these different active ingredients and knows of no lawful basis for compounding them.
5. Retatrutide or cagrilintide offered as a compounded product. FDA states these cannot be used in compounding under federal law, and they aren't components of any approved drug.
6. "Research use only" or "not for human consumption" on the label. That isn't a pharmacy pathway. It's a workaround.
7. Marketing that calls it FDA-approved, generic, "the same as" a brand, or clinically proven equivalent. FDA has taken action against exactly this language.
8. The label names a pharmacy that doesn't exist — or one that says it didn't make your product. FDA has documented both. Do not use the product until the pharmacy identity is resolved; contact the named pharmacy and the telehealth platform in writing.
9. Nobody can reconcile milligrams, milliliters, units, and syringe size. If your prescriber and your pharmacy give different numbers, do not guess. Do not average. Do not ask a Facebook group.
10. It arrives warm and they tell you to use it anyway. FDA recommends not using an injectable GLP-1 that arrives warm or without enough refrigeration.
11. No licensed doctor is available to answer questions after delivery. FDA lists this as a telehealth warning sign. Your dispensing pharmacist should also be reachable for product and label questions.

⚠️ And here's what is not a hard stop

This part matters just as much, and you won't find it on most pages. Fear sells, and a lot of "red flag" lists will talk you out of a perfectly reasonable pharmacy. These are yellow flags — ask one more question, don't walk:

• No PCAB or NABP accreditation. Both are voluntary. Having it is a real positive signal. Not having one is not proof that a pharmacy is unsafe.
• They won't email you the full certificate of analysis. A pharmacy may decline to share a supplier document. Refusing to send the document is different from refusing to explain what's tested. The second one is the problem.
• An old FDA Form 483. A 483 is a list of what an inspector observed during a visit. It is not a final finding that a violation occurred. Ask what was observed, how the facility responded, and where it stands now.
• The company uses more than one pharmacy. Networks are normal — different states, different formulations. The question is whether you can find out which one is yours, in time.
• Ice packs that arrived partly melted. Ice-pack appearance is not a temperature reading. Ask for the storage range and the written policy instead of guessing.
• A low price. Price alone proves nothing. It's a reason to ask what got funded and what didn't, not a verdict.
• One bad review. Patterns matter. Single reviews don't.

If you're sitting in the yellow zone with two or three unanswered items and no idea whether that's normal, that's a genuinely hard call to make alone.

Not sure which lane fits you? Take the free 60-second matching quiz → Free. No email. Five quick questions about your goals, budget, and preferences — then a specific next step.

---

Answer capsule: A 503A pharmacy is state-licensed and fills prescriptions for identified patients. A 503B outsourcing facility registers with FDA, must follow current Good Manufacturing Practice, can make batches without patient-specific prescriptions, and is subject to FDA inspection. For semaglutide and tirzepatide, FDA says neither drug is on the 503B bulks list or the shortage list. Those are the two main statutory routes for a 503B to compound from raw active ingredient. So "we use a 503B" is not a green light by itself. Ask one more question.

Let's unpack that slowly, because it's the single most useful thing on this page and almost nobody has caught up to it.

A 503A pharmacy — the "A" comes from Section 503A of the Federal Food, Drug, and Cosmetic Act — is a regular state-licensed compounding pharmacy. It compounds for an identified patient based on a valid prescription. State boards of pharmacy handle day-to-day oversight.

A 503B outsourcing facility registers with FDA, must follow current Good Manufacturing Practice, and is subject to FDA inspection. It can make batches without individual patient names. Registration alone does not mean FDA found the facility compliant.

On paper, 503B sounds better because it adds federal registration, current Good Manufacturing Practice requirements, product reporting, adverse-event reporting requirements, and FDA inspection. That is why you'll see the advice everywhere: ask whether they use a 503B.

Here's the catch. A 503B can only compound from a bulk ingredient (the raw active powder) if one of two things is true:

• the ingredient is on FDA's 503B bulks list, or
• the drug is on FDA's drug shortage list at the time it's made, distributed, and dispensed.

FDA's April 1, 2026 statement says plainly that tirzepatide and semaglutide do not currently appear on the 503B bulks list. They're not on the shortage list either — FDA found the tirzepatide shortage resolved on December 19, 2024, and the semaglutide shortage resolved on February 21, 2025.

Then on April 30, 2026, FDA proposed not to add semaglutide, tirzepatide, or liraglutide to that bulks list, saying it found no clinical need for 503B facilities to compound them from bulk substances. The proposal ran in the Federal Register on May 1, 2026 (91 FR 23431). The comment window was extended once and closed July 30, 2026. As of August 8, 2026, we found no final determination in the Federal Register or FDA's current compounding-policy list.

So the two main statutory doors for routine 503B compounding from bulk semaglutide or tirzepatide are shut right now: neither drug is on the shortage list, and neither appears on the 503B bulks list.

What that means for your conversation. If a seller tells you "we use a 503B outsourcing facility," you say:

"Thanks — is my medication compounded from bulk semaglutide, or from an FDA-approved finished drug?"

That single follow-up is worth more than the original question. It's polite, it's specific, and the answer tells you whether they actually know their own supply chain.

Why the old shortcut still shows up. For many sterile compounded drugs, 503B status can be a useful quality and oversight signal. That general rule is why older checklists say to prefer a 503B. But it does not answer the drug-specific bulk-substance question for semaglutide or tirzepatide. The market changed underneath the shortcut.

We're not telling you 503B means something is wrong. We're telling you the shortcut everyone recommends stopped working for these two drugs, and now you have to ask the second question.

Want the full breakdown of the two pharmacy types? See our 503A vs 503B compounding pharmacy guide.

---

Answer capsule: Ask for semaglutide base. Semaglutide sodium and semaglutide acetate are salt forms, and FDA states they are different active ingredients from the one used in approved drugs and that it is not aware of any lawful basis for their use in compounding. Mississippi and New Jersey pharmacy-board guidance follows the same chain: semaglutide has no USP or NF monograph, the approved drugs use semaglutide base, and the salt forms are not components of those approved drugs. A seller who confirms a salt form has answered the question for you.

Most guides say "salt forms are concerning." That's true but useless, because you can't argue with a seller using the word "concerning." Here's the actual rule, step by step, and it's worth understanding because it turns a vague worry into a hard line.

Under Section 503A, a compounding pharmacy can only use a raw ingredient if it clears one of three tests, in order:

1. Does it meet a USP or National Formulary monograph? A monograph is a public quality recipe — identity, strength, purity, and the tests to prove it. If one exists, the ingredient must meet it.
2. If no monograph exists, is the ingredient a component of an FDA-approved drug?
3. If neither, is it on FDA's 503A bulks list?

For 503A compounding from a bulk drug substance, two more conditions apply: the substance must come with a valid certificate of analysis, and it must be made by a facility registered with FDA.

Now run semaglutide through it. Two state boards of pharmacy already did.

The Mississippi Board of Pharmacy's compounding guidance says it in one line: semaglutide does not have a USP or NF monograph. Step one is out. So we're on step two — is it a component of an approved drug? The same guidance answers that too: semaglutide base is in the approved products, "but not semaglutide sodium, semaglutide acetate or other salt forms." The New Jersey Board of Pharmacy published a statement reaching the same bottom line on semaglutide compounding.

That is the key chain: no monograph → semaglutide base qualifies as a component of approved drugs → the salt forms are not components of those drugs. FDA then closes the remaining question by saying it is not aware of any lawful basis for using the salts in compounding.

So when you ask question 8 and the answer is "semaglutide sodium," you're not making a judgment call about quality. You're looking at an ingredient FDA says has no known lawful basis for compounding.

How to word it so you get a straight answer:

"Is the active ingredient semaglutide base, or a salt form such as semaglutide sodium or semaglutide acetate? Please confirm in writing."

Ask for it in writing specifically. Verbal answers evaporate. And if they dodge the word "base," that's your answer.

The Ohio Board of Pharmacy makes the parallel point for tirzepatide: Mounjaro® and Zepbound® contain tirzepatide base, not a salt form.

---

Answer capsule: Some compounded GLP-1s include added ingredients such as vitamin B12, and sellers often present that as personalization. In March 2026 Eli Lilly said its testing found a previously unidentified impurity created when tirzepatide was mixed with B12, with unknown effects in humans. A 2026 peer-reviewed paper by Lilly-affiliated authors reported the same interaction. The compounding trade group challenged the lack of public sample and testing detail. Ask for a complete ingredient list with amounts, including any preservative.

Adding something is one common way sellers argue their product isn't just a copy of the brand. Sometimes there's a genuine clinical reason. Often there isn't.

FDA addressed this directly on April 1, 2026, and used semaglutide combined with vitamin B12 as an example of a product that may still count as essentially a copy. In that example, FDA described the semaglutide and B12 amounts as within 10% of the strengths in the relevant commercially available products. In other words, dropping a vitamin into the vial doesn't automatically make it a different medicine in FDA's eyes.

Then the chemistry showed up.

On March 12, 2026, Eli Lilly published an open letter saying its testing found a previously unidentified impurity created when tirzepatide is mixed with vitamin B12. Lilly said nothing is known about the impurity's short- or long-term effects in people, its toxicity, its immune effects, or whether it changes how tirzepatide works at its targets. A 2026 paper in a peer-reviewed drug-safety journal reported the same interaction; every listed author was affiliated with Eli Lilly. Lilly also named other additives it said it was seeing in the market: glycine, pyridoxine (B6), niacinamide, and carnitine.

And now the balance, because you deserve it. Eli Lilly makes the brand-name product and has an obvious commercial interest in compounded versions going away. The Alliance for Pharmacy Compounding — the compounding industry's trade group — said Lilly had not published enough information about sample sources, handling, the identity of the impurity, or the amount found for outsiders to judge the claim. Both of those things are true at once. Lilly also states that tirzepatide has not been studied in combination with B12.

Stanford Medicine's clinicians make a related point about the additive menu generally — B12, B6, niacinamide, glycine, carnitine — noting these have no proven benefit for weight loss or diabetes management and that the combinations are largely untested in trials.

How to ask:

"Please list every ingredient in the vial and its amount, including any preservative."

A complete list is a fine answer. "Proprietary blend" is not an ingredient list. And "a body-safe vitamin" is marketing. FDA warning letters have challenged similar language that makes an unapproved compounded drug sound proven or equivalent.

Two absolute stops here: FDA states that retatrutide and cagrilintide cannot be used in compounding under federal law, and that they aren't components of any FDA-approved drug and haven't been found safe and effective for any condition. If either is on the menu, that tells you what kind of operation you're dealing with — even if you weren't going to order it.

---

Answer capsule: A certificate of analysis is a report on one batch of ingredient — its identity, assay, and tested impurities. A valid certificate is a condition for a 503A pharmacy using a bulk drug substance, so a simple yes-or-no question does little work. The useful questions are which lot it covers, what specification it was measured against, who owns that specification, and which lab ran the test. Semaglutide has no USP monograph, so the working standard may be a private supplier or manufacturer specification rather than a public USP standard.

Ask only "do you have a certificate of analysis?" and a yes tells you very little. For 503A bulk ingredients, a valid certificate is already one of the conditions in federal law. The useful work starts with the lot, the specification, and the lab.

Here's the part that almost nobody publishes.

Because there's no USP monograph for semaglutide, there is no public USP standard for that certificate to use. Brookings put the gap plainly in April 2025: without a monograph or the drug-master-file review that comes with an approval application, bulk manufacturers are effectively setting their own product specifications.

Sit with that for a second. "99.2% pure" means 99.2% against the specification named on that report. That specification may belong to the manufacturer or supplier. That's not nothing. It's also not what most people picture when they hear "certified."

Turn one dead question into three live ones

1. Is this certificate for the exact ingredient lot used in my medication, or is it a sample? A blank example certificate proves the document format exists. Nothing more.
2. What specification was it tested against, and who wrote that specification? If the answer is the supplier's own spec, fine — now you know what the number means.
3. Which lab ran the test — the ingredient supplier, the pharmacy, or an independent lab?

The gap most people never notice

There are two completely different pieces of evidence here, and sellers blur them constantly:

FDA's January 2026 warning letter to Boothwyn Pharmacy described a finished tirzepatide/B12/glycine lot that failed sterility testing, plus finished semaglutide and tirzepatide lots that were below labeled strength. Ingredient paperwork alone would not answer either finished-product problem. So the follow-up is question 11 on our list:

"What testing or release checks apply to the finished preparation, not just the raw ingredient? Who performs them, and what can you share about my lot?"

Fair warning about the answer. A 503A pharmacy is not under one universal federal rule requiring every possible test on every individual vial, and a pharmacy declining to email you a supplier document is not automatically hiding something. What should worry you is a pharmacy that can't describe its release controls at all, or one that hands you the raw-ingredient certificate and calls it proof your vial is sterile. Those are different failures, and only one of them is disqualifying.

---

Answer capsule: The first question goes to FDA's essentially-copy framework: did your prescriber determine and document a change that produces a significant difference for you? The second goes to FDA's current enforcement policy: FDA says it does not intend to take action for the "regularly or inordinate amounts" condition when a compounder fills four or fewer prescriptions of that compounded drug product in a calendar month. Four is an enforcement-discretion threshold. It is not a legal ceiling, a permission slip, a per-patient allowance, or a safety score.

Consider these a bonus. They come straight from FDA's copy framework and current enforcement policy, and they're the two that tell you the most.

Question A: "What's written in my chart?"

Under FDA's framework, a compounded product with the same API, a same or easily substitutable strength, and the same route may be considered essentially a copy unless the prescriber determines and documents a change that produces a significant difference for the identified patient. Not for patients in general. For you.

In practice, the reasons that hold up are things like: a documented reaction to an inactive ingredient in the approved product, a dose strength that isn't commercially sold, or a delivery route you genuinely need.

So ask:

"What change did my prescriber determine makes this compounded version significantly different for me, and is that determination documented in my chart?"

If the answer is "it's cheaper," or "everyone on this plan gets the same formulation," that does not describe a patient-specific change that produces a significant difference. It doesn't mean anyone is doing something wrong to you. It means the answer under your prescription is thinner than the marketing suggests. You're allowed to know that before you build a year of treatment on it.

Question B: "How many of these do you fill in a month?"

Here's the number nobody has told you.

FDA's stated enforcement policy is that, at this time, it does not intend to take action over the "regularly or in inordinate amounts" condition when a compounder fills four or fewer prescriptions of that compounded drug product during a calendar month.

Four.

Now hold that next to a telehealth platform advertising one "personalized formulation" to the entire internet — and ask whether it is relying on a documented significant difference for each identified patient, the four-prescription enforcement policy, or some other legal theory.

Will they answer? Almost certainly not. We want to be straight with you about that. So why ask?

Two reasons. First, because a company that gives you a straight number is telling you something extraordinary about how it operates. Second, because now you understand what the number means — and you will not mistake FDA's enforcement discretion for proof that a mass-marketed formula is lawful for every patient.

One correction while we're here. We've seen this policy described as four prescriptions per patient per month. FDA's own sentence says four or fewer prescriptions of that compounded drug product during a calendar month. It does not say per patient. It also does not call four a legal cap. It tells you when FDA currently says it does not intend to act on one specific condition.

---

Answer capsule: Before drawing a dose, get three numbers in writing: the concentration printed on your vial in milligrams per milliliter, how many syringe units to draw for your prescribed dose, and the syringe size to use. FDA has documented patients self-administering five to twenty times their intended dose, largely from confusion between milligrams, milliliters, and units. If your prescriber's number and your pharmacy's number don't match, don't inject — call.

This is the section most likely to prevent a dosing emergency, and it has nothing to do with legality.

FDA-approved pens use preset or device-selected doses. A compounded multidose vial has none of that built in. You get liquid in a bottle, a syringe, and a number someone typed into a portal.

Here's what FDA documented:

• Patients told to draw a 5-unit dose — 0.05 mL — drew 50 units instead, which is 0.5 mL. Ten times the dose.
• The majority of the reports described patients drawing too much. In those cases, patients took 5 to 20 times the intended dose.
• It wasn't only patients. One prescriber meant 0.25 mg — 5 units — and wrote 25 units. Another wrote 20 units instead of 2, and three patients were affected.
• FDA's stated cause: unfamiliarity with drawing from a vial, plus confusion between milligrams, milliliters, and "units."
• And the trap underneath all of it: a single compounder may offer several different concentrations. So "5 units" isn't a dose. It's a volume. What's in that volume depends entirely on your vial.

FDA's guidance to compounders and prescribers is to hand patients the right syringe and teach them how to measure. FDA's own alert notes that instructions come with the drug "if provided" — which tells you they don't always.

Stanford Medicine's clinical pharmacist put the confusion plainly: even for clinicians, he said, looking at these products, it's not always clear.

The three numbers, and the one sentence that protects you

Write these down before you open anything:

1. Concentration: ______ mg per mL (read it off the vial, not the website)
2. My dose: ______ mg = ______ units on a ______ mL syringe
3. Syringe size they're sending: ______

Then say this to your pharmacist or prescriber, out loud, and let them correct you:

"I'm drawing ___ units, which is ___ milligrams, once a week. Is that right?"

That's called a teach-back, and it's a simple safety step that catches misunderstandings before the needle does.

If three sources disagree — the vial, the printed sheet, and the portal — do not pick one. Do not average them. Do not search for the answer. Photograph all three and get one corrected written instruction from the pharmacy or your prescriber before you inject anything.

If you're on a compounded product now and the numbers have never been explained to you, that's worth a message today, not at your next refill.

---

Answer capsule: Follow the storage range printed for your specific preparation. FDA says injectable GLP-1 drugs require refrigeration as stated in their package inserts and recommends not using one that arrives warm or with insufficient refrigeration. On arrival, check for warmth or damage, confirm the pharmacy name on the label matches the one you verified, and look for a lot number and beyond-use date. FDA has documented fraudulent labels naming pharmacies that do not exist and real pharmacies that did not make the product.

What if it arrives warm?

FDA has received complaints that compounded GLP-1s arrived warm or with too little ice, and its recommendation is direct: don't use it. Heat can affect quality.

One honest note about ice packs. A melted ice pack is not a thermometer. Ice can be gone while the product stayed in range, and product can get too warm while some ice remains. That's why the useful thing is the policy, not your judgment on the doorstep.

Ask before you order:

"What temperature range does this preparation need, and what is your written policy if it arrives warm, damaged, or late?"

If it does arrive warm: don't use it, photograph the box, the ice packs, the vial, and the delivery time, then contact the pharmacy and the company in writing the same day. Ask for a documented determination and a replacement.

What to check on the label

Four things, in about fifteen seconds. Exact legal label requirements can vary by pharmacy type and state, but these are the checks you need:

• The pharmacy name matches the one you verified. If it doesn't, stop and call the pharmacy printed on the label. That is the fastest way to test the mismatch; FDA has documented labels naming pharmacies that don't exist, and labels naming real pharmacies that didn't make the product.
• Your name, spelled correctly, and your prescriber's name.
• The medication and concentration — and it should say semaglutide or tirzepatide, not "sodium" or "acetate."
• A lot number and a beyond-use date. Missing dates are on Stanford's red-flag list. And keep that lot number — recall notices identify the affected product and lot.

Going deeper on labels is a whole job of its own. We built a separate one: GLP-1 pharmacy label red flags — 18 checks before you inject.

The beyond-use date math nobody does

A beyond-use date, or BUD, is not the same thing as the expiration date on a manufactured drug. It's the date the pharmacy assigns based on the standards it follows, the formulation, and any stability data it has.

Here's the arithmetic that catches people, and it's simple:

If you're buying a three-month supply and the beyond-use date is eight weeks out, part of what you paid for reaches its beyond-use date before you can use it.

That's it. That's the whole trap. Multi-month plans are often the cheapest per month, which is exactly why this needs asking:

"What's the beyond-use date on my vials, and will my entire prescribed supply be used before that date? If not, what happens?"

A good answer is a date and a plan. A bad answer is being told to ignore the date.

---

Answer capsule: Telehealth companies may use more than one pharmacy and may change partners, formulations, or concentrations between fills. That isn't a red flag by itself. What matters is whether you're told before the next fill, whether your dose instructions are re-checked against the new concentration, and whether you can decline.

Pharmacy networks are normal. Different states, different formulations, different capacity. Plenty of legitimate companies run them.

The problem isn't the network. The problem is finding out after the fact.

A change matters because a new pharmacy can mean a new concentration — and a new concentration means your unit count changes even though your milligram dose didn't. That is exactly the setup FDA described in its dosing-error alert.

Ask this now, before your first order:

"Can the pharmacy, concentration, route, additives, or formulation change on a future fill? Will you notify me before that fill, and can I decline?"

And re-run this entire page's checklist any time one of these happens:

• The pharmacy name changes
• The concentration changes
• The dosage form or route changes
• An additive appears or disappears
• Your directions change
• A recall, warning letter, or state action involves your pharmacy

If your provider already switched on you, we wrote the follow-up: what to do when your compounding pharmacy shuts down or changes 503A status.

---

Answer capsule: Ask for the total first charge and the normal recurring charge separately. Some cash-pay GLP-1 programs use an introductory price; others use prepaid multi-month pricing. Confirm what a dose increase costs, whether supplies and shipping are extra, when the renewal hits, what the cancellation deadline is, and what happens if a clinician declines to prescribe.

Billing is the least dramatic section on this page and one of the easiest places to make an expensive mistake.

Get these in writing, all of them, in one answer:

That last row is the one to circle. The non-refundable trigger is your real deadline. It may be when the clinician approves treatment, when the prescription is sent, when the pharmacy starts work, or when the order ships. Ask for the exact event before you pay.

Save the billing date, the cancellation confirmation number, and a screenshot of the terms. Boring. Works.

---

Answer capsule: Federal law does not require state-licensed pharmacies that are not outsourcing facilities to submit adverse event reports to FDA, and FDA says that's why reports from compounded products are likely undercounted. As of May 31, 2026, FDA had received 990 adverse event reports for compounded semaglutide and more than 730 for compounded tirzepatide. Patients can report directly to FDA through MedWatch without the pharmacy's involvement.

This is the quiet one, and it changes how you read every safety statistic you've ever seen about compounded GLP-1s.

Consumer compounded GLP-1 orders may be filled by state-licensed pharmacies operating outside Section 503B. Read FDA's own words about that group: federal law does not require state-licensed pharmacies that aren't outsourcing facilities to submit adverse events to FDA — so FDA says reports from compounded versions are likely undercounted.

If your pharmacy is state-licensed and is not a 503B outsourcing facility, federal law does not require it to submit your adverse event to FDA.

Eli Lilly made the same point in its March 2026 company letter about tirzepatide/B12 products. That is a manufacturer statement, not independent evidence, but it matches FDA's description of the federal reporting gap.

That's why the counts below are an incomplete signal, not a rate:

The two published drug-specific figures total more than 1,720 reports. FDA also says it is not always possible to determine whether the drug caused a reported event or whether other factors contributed. These are reports, not a proven rate — and FDA says the reporting gap means they are not a complete count either.

So ask two questions, and take the honest answer:

"If I have a bad reaction, who do I tell? Do you report adverse events to FDA?"

The best possible answer sounds like this: "We're not required to, we do anyway, and here's how you can report it yourself." A company that says that is not being modest. It's being accurate.

You can report it yourself. FDA's MedWatch program takes reports directly from patients — no permission needed from anyone. Your report is part of how the signal gets built at all.

Step-by-step: how to report a bad GLP-1 experience to FDA MedWatch.

---

Answer capsule: Once you have the pharmacy's legal name, two public records are open to you. Your state board of pharmacy's license database shows whether that pharmacy is authorized to ship to your state, and FDA's Drug Establishments Current Registration Site shows whether an ingredient manufacturer is federally registered. Both are free and neither requires the seller's cooperation.

1. Your state board of pharmacy. Search "[your state] board of pharmacy license lookup." You're checking for active status, any listed restrictions or discipline, and — for an out-of-state pharmacy — a non-resident license in your state. FDA's guidance is blunt: if an online pharmacy isn't listed in the state database, don't use it.

2. FDA's DECRS database (Drug Establishments Current Registration Site). This is where you check the ingredient maker they named in question 9. It's searchable by firm name, city, state, or FEI number, and it's updated every business day. Two things to know about it:

• A facility is removed automatically if FDA inactivates its registration because of a compliance case or enforcement action, if registration expires, or if it deregisters. An absence matters, but first check the exact legal name and FEI because names can differ.
• Use FDA's separate Registered Outsourcing Facilities page to verify a claimed 503B. A firm may appear in more than one FDA system for different operations; the outsourcing-facility list is the direct check for 503B status.

And the essential caveat, in FDA's own words: registering an establishment and listing drugs does not indicate the products are approved or that FDA has verified the information provided. Registration is a floor test. It's the difference between "this facility exists in the federal system" and "this facility makes good product." Only the first one is being tested.

The full walkthrough — every lookup, what to search, how to read a warning letter — lives on our 503A pharmacy verification guide. Bookmark it and run it once per provider.

---

Answer capsule: Compounded GLP-1s are the wrong fit for someone who has insurance coverage for a brand-name product, who wants FDA premarket review of the finished medication, who has no patient-specific need an available FDA-approved product cannot meet, or who doesn't want the ongoing verification work this page describes. Choosing an FDA-approved product removes most of the questions on this page, because the manufacturer, strength, and label are fixed and adverse event reporting is required.

We'd rather send you somewhere better than convert you into something you'll reverse in two months.

Compounded is the wrong path if:

• You have insurance that might cover Wegovy or Zepbound. Run a free coverage check before you self-pay for anything. The gap between a covered copay and a cash price can be the whole decision.
• An available FDA-approved product can meet your medical need. If you do not need a different ingredient, strength, dosage form, or other patient-specific change, FDA says the compounded route should not be the default. A provider who approves the same mass-market formula anyway is handing you a regulatory question you'll be carrying.
• You want FDA review of the finished medicine. That only exists with approved products. There's no version of a checklist that creates it.
• You'd rather not do any of this. That's a legitimate, adult choice. It means compounded isn't your fit — not that you're lazy.

What actually changes if you go FDA-approved

Count the questions that disappear:

Most of the compounding-specific questions stop applying. That's not marketing. That's just what the approval process already did for you.

Ro is our most direct recommended path to FDA-approved GLP-1s for cash-pay and insured patients alike. Verified on Ro's own pricing page on August 8, 2026: Ro Body membership is $39 for the first month, then as low as $74/month with an annual plan paid upfront, or $149/month month-to-month. Medication is billed separately. Ro's page also states the $39 is refunded if you're not eligible for a GLP-1.

Ro's current pricing page shows cash-pay Wegovy® pill, Foundayo® pill, Wegovy® pen, and Zepbound® KwikPen®. Its insurance pathway checks coverage for Ozempic®, Wegovy® pen, and Zepbound® autoinjector pen. Ro says its cash-pay prices match manufacturer-direct programs, and it offers a free insurance coverage check for select products plus an insurance concierge that handles prior-authorization paperwork.

The honest limit: the membership is a second bill on top of medication, and insurance doesn't cover it. If you only want a prescription and nothing else, that's real money for a service you may not use. Ro says only Wegovy pen, Zepbound autoinjector pen, and Ozempic are currently available for its insurance pathway; some other products are cash-pay only. Government-plan eligibility and support can differ, so confirm your exact plan before paying.

Run Ro's free GLP-1 insurance coverage check → It's free, it takes a couple of minutes, and it's the highest-value thing you can do before paying cash for anything. Sponsored link.

---

Answer capsule: If a compounded GLP-1 is the realistic option, the most useful first check is whether the company publishes its pharmacy partners and will identify the pharmacy assigned to your prescription before the medication charge becomes non-refundable. A public partner list is useful. It is not the same as knowing which pharmacy will fill your order.

Cost is why most people are reading this page. We're not going to pretend otherwise, and we're not going to lecture you about it.

So here's the practical version. These are provider-stated facts we checked on August 8, 2026. We did not independently inspect the pharmacies or verify which one any new patient would receive.

Provider links in this table are sponsored links.

The honest tradeoff (our one damaging admission)

Neither Embody nor Enhance.MD gives you a complete answer to question 1 on its public page. Embody names four partner pharmacies. Enhance.MD names three and also says it may use other licensed pharmacies. That is better than a blank "network" claim, but it is still a partner list — not your assignment.

If the lowest advertised starting price is your priority, Embody gets the first look right now: $79/month for GLP-1 injections and $129/month for GLP-1/GIP injections under its current summer promotion. But the starting number is tied to plan length. Do not compare $79 with another company's monthly price until you know the full prepaid commitment, the exact drug, and what happens if you cancel.

Enhance.MD's public terms give you three specific buildings to research, but the words "and other licensed pharmacies" keep it from being a passing answer before intake. Ask which pharmacy is assigned to you and whether that assignment can change.

One thing to know either way, and we'd rather you hear it from us: Enhance.MD's published GLP-1 page says compounded medications "contain the same active ingredients" as brand-name drugs. FDA has called that style of claim false or misleading in warning letters to other telehealth companies. We found no FDA warning letter to Enhance.MD in the sources checked for this page, but you should know the agency's posture on that wording when you read anyone's marketing — including a company we're discussing here.

See Embody's current pricing and plan terms → Check Enhance.MD's pharmacy-partner terms and eligibility → Both routes use compounded medication. Compounded drugs are not FDA-approved. A licensed clinician decides whether treatment is appropriate. Sponsored links.

Three companies we're not recommending here, and why

We take commissions from all three of these. We're leaving them off anyway, because this page is specifically about pharmacy transparency and compounded-drug marketing, and it would be absurd to feature them:

• MEDVi — FDA Warning Letter #721455 (February 20, 2026). FDA said MEDVi's pictured labels falsely or misleadingly suggested MEDVi was the compounder when it was not, and FDA objected to "same active ingredient" claims.
• MyStart Health — FDA Warning Letter #714755 (September 9, 2025). FDA said "Generic Ozempic" and "same active ingredients and results" claims falsely implied that compounded semaglutide was the same as an FDA-approved product.
• DirectMeds — FDA Warning Letter #716822 (September 9, 2025). FDA said claims that compounded semaglutide or tirzepatide used the "same active ingredient" and was an effective alternative were false or misleading.

If you're already using one of them, a warning letter is not a reason to stop a prescription on your own. Ask your clinician and dispensing pharmacy what you are receiving, send questions 1 and 7, and ask whether the language FDA flagged has been corrected. Save the reply.

Full breakdown with sources: GLP-1 providers that use 503A pharmacies*.

---

Named sources, shown for context on how professionals read the same market — not as proof that one specific vial is good or bad:

"Nobody legitimate makes sublingual semaglutide." — Michael Blyumin, PharmD, ambulatory clinical care pharmacist, Stanford Medicine

Speaking about compounded product information, Blyumin also said that even for clinicians, it's not always clear how much drug is in the bottle.

For balance, the compounding industry's side: Alliance for Pharmacy Compounding CEO Scott Brunner said Lilly had not published enough information about the source, handling, identity, or amount of the impurity in its tirzepatide/B12 samples for outsiders to evaluate the claim. He called for the data to be shared with regulators and the public.

We include that last one on purpose. A page that only quotes the drug companies isn't a fair page.

---

Answer capsule: Weight Loss Provider Guide is an independent comparison resource for GLP-1 telehealth providers. This page was built from FDA policies, safety communications, warning letters, and public databases; three state pharmacy-board sources; the Federal Register; a manufacturer letter and the compounding trade group's response; a peer-reviewed paper; an academic medical center's consumer guidance; and current provider pages. No product was purchased, tested, or lab-analyzed for this page.

Written by the Weight Loss Provider Guide Research Team. We don't invent author credentials, we don't add a "medically reviewed by" line we haven't earned, and we don't publish testimonials we can't attribute.

Why this page exists: because the advice on this topic is either a list of questions with no way to grade the answers, or a fear list that talks you out of a reasonable pharmacy. Neither one helps you at checkout. This is the version we'd hand a friend.

Where we correct a common shortcut, we show the underlying record. The two biggest are the four-prescription figure — an FDA enforcement-discretion threshold, not a legal ceiling or per-patient allowance — and the idea that "503B" alone answers the semaglutide or tirzepatide bulk-substance question.

What remained unresolved on August 8, 2026: FDA's final determination on the proposed 503B bulks-list exclusions. The comment period closed July 30, 2026, and we found no final determination in the Federal Register or FDA's current policy list.

Found an error? Email editorial@weightlossproviderguide.com. We correct verified errors within five business days. We updated our own adverse-event figures on this page for exactly that reason.

Update schedule: monthly for the 503B bulks list status, provider pricing, and pharmacy disclosures. Quarterly for FDA policy language, adverse-event totals, and every outbound lookup link. Same-week updates for a major FDA decision, court ruling, or recall.

This page is information, not medical advice. GLP-1 medications require evaluation by a licensed clinician. Talk to a qualified healthcare provider before starting, stopping, or changing any medication.

---

What is the single most important question to ask a GLP-1 compounding pharmacy?

Which pharmacy will make and ship your medication — the legal name, city, and state. Every other check on this page depends on having that name. You can't look up a license, a warning letter, or a recall for "our network of licensed pharmacies."

Who should answer my pharmacy, prescription, and dose questions?

The telehealth company should explain pharmacy assignment, pricing, changes, and cancellation. The prescriber owns the medical reason, prescription, and dose. The pharmacy owns the formulation, ingredients, testing, beyond-use date, label, and shipping. Ask the company to route each question to the right desk and reply in writing.

Do I have a right to see the certificate of analysis?

The federal 503A provision requires a valid certificate for the bulk substance, but it does not say the pharmacy must provide that certificate to each patient. So a refusal to send the paperwork is different from a refusal to explain what's tested. The second one is the real problem.

Is compounded semaglutide legal in 2026?

It depends on the pharmacy, your state, the prescription, the formula, and the facts supporting it. Broad shortage-based copy compounding ended in 2025. Under FDA's framework, a 503A product that would otherwise be an essentially identical copy may avoid that classification when the prescriber documents a change that produces a significant difference for the identified patient. FDA also says it currently does not intend to act on the "regularly or inordinate amounts" condition when a compounder fills four or fewer prescriptions of that compounded drug product in a calendar month. That is enforcement discretion, not a legal safe harbor or safety finding.

Is a 503B outsourcing facility safer than a 503A?

A 503B must register with FDA, follow current Good Manufacturing Practice, report products and follow federal adverse-event reporting requirements, and is subject to FDA inspection. Registration is still not approval or proof of current compliance. For semaglutide and tirzepatide, FDA says neither drug is on the 503B bulks list or shortage list. If a seller says 503B, ask whether your medication is made from bulk ingredient or from an FDA-approved finished drug.

Is semaglutide sodium the same as semaglutide?

No. FDA states that semaglutide sodium and semaglutide acetate are different active ingredients from the one used in approved drugs, and that it is not aware of any lawful basis for their use in compounding. Mississippi and New Jersey guidance explains why the base is the approved-drug component; FDA closes the remaining question by saying it is not aware of any lawful basis for using the salt forms in compounding.

Is there such a thing as an FDA-approved compounding pharmacy?

No. FDA approves drugs, not pharmacies. A 503B outsourcing facility registers with FDA, but registration is a filing, not an approval — FDA states that registering and listing drugs does not mean the products are approved or that FDA verified the information. Compounded drugs are not FDA-approved, whether they come from a 503A or a 503B.

What if my provider won't name the pharmacy?

Don't let the medication charge become non-refundable until you have the name. A network is not the problem; not being able to identify your own pharmacy in time is. If you already ordered, the name will be on the label — and if the label name doesn't match what you were told, call the pharmacy on the label and ask whether the product is theirs.

Should I ask for a certificate of analysis for my specific lot?

Yes, and then ask three follow-ups: does it cover the ingredient lot used for my medication, what specification was it measured against and who owns that specification, and which lab ran the test. Because semaglutide has no USP monograph, the report may rely on a private supplier or manufacturer specification rather than a public USP standard.

What if my compounded GLP-1 arrives warm?

Don't use it. FDA recommends against using an injectable GLP-1 that arrives warm or with insufficient refrigeration. Photograph the box, the ice packs, the vial, and the delivery time, then contact the pharmacy and the telehealth company in writing the same day and ask for a documented determination and replacement.

How many units of compounded semaglutide should I draw?

There's no universal answer, and that's the point — the unit count depends on your vial's concentration in milligrams per milliliter, which varies between compounders and can even vary within one compounder. Get your dose in milligrams, the concentration in mg/mL, and the matching unit count from your prescriber or pharmacist in writing. FDA has documented patients drawing five to twenty times their intended dose from this exact confusion.

Can I report a bad reaction to compounded semaglutide myself?

Yes, through FDA's MedWatch program, without needing the pharmacy's involvement. This matters because federal law does not require state-licensed pharmacies that aren't outsourcing facilities to report adverse events to FDA, which FDA says is why compounded-product reports are likely undercounted.

Does an active pharmacy license mean the medication is safe?

No. A license confirms the pharmacy is currently authorized under the record you're looking at. It says nothing about whether one particular vial is sterile, correctly dosed, correctly labeled, or right for you. That's true of accreditation and FDA registration too — they're floors, not guarantees.

Is a low price proof that a compounded GLP-1 is unsafe?

No. Price alone proves nothing. It's a reason to ask what the price includes — testing, clinician access, supplies, cold shipping — not a verdict on quality.

What about compounded pills, drops, or dissolving tablets?

FDA-approved semaglutide products include injections and oral tablets; FDA-approved tirzepatide products are injections. Compounded sublingual drops and dissolving versions have not gone through FDA approval, and Stanford Medicine's clinical pharmacist said in July 2026 that he had never seen absorption data for sublingual semaglutide and that "nobody legitimate makes" it. If that's the form you're considering, ask more questions, not fewer.

Can I ask all of this without sounding difficult?

Yes, and you should. Here's the polite one-line version to open with: "Before my medication charge goes through, could you confirm a few details in writing for my records?" Nobody reasonable is offended by that. A company that is offended by it has told you something useful for free.

---

Take our free 60-second matching quiz. Answer five quick questions about your goals, budget, and preferences — and get a specific next step instead of another twelve tabs.

Get my personalized GLP-1 action plan →

No email. No spam. Just a specific recommendation and the reason behind it.

And whichever way you go: send the sixteen questions first. It takes ninety seconds and can save you from paying before the basic facts are clear.

---

Federal regulators and law

1. U.S. Food and Drug Administration. "FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss." Content current June 15, 2026.
2. U.S. Food and Drug Administration. "FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize." April 1, 2026.
3. U.S. Food and Drug Administration. "Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act."
4. U.S. Food and Drug Administration. "FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products."
5. U.S. Food and Drug Administration. "FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List." April 30, 2026.
6. Federal Register. "List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B." 91 FR 23431, May 1, 2026, and comment-period extension to July 30, 2026.
7. U.S. Food and Drug Administration. "FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s." March 3, 2026.
8. U.S. Food and Drug Administration. "FDA Intends to Take Action Against Non-FDA-Approved GLP-1 Drugs." February 6, 2026.
9. U.S. Food and Drug Administration. Drug Establishments Current Registration Site (DECRS).
10. U.S. Food and Drug Administration. Registered Outsourcing Facilities.
11. U.S. Food and Drug Administration. Electronic Drug Registration and Listing System (eDRLS).
12. U.S. Food and Drug Administration. "BeSafeRx: Locate a State-Licensed Online Pharmacy."
13. U.S. Food and Drug Administration. Warning Letter #717525 to Boothwyn Pharmacy, LLC. January 16, 2026.
14. U.S. Food and Drug Administration. Warning Letter #721455 to MEDVi, LLC. February 20, 2026.
15. U.S. Food and Drug Administration. Warning Letter #714755 to MyStart Health LLC. September 9, 2025.
16. U.S. Food and Drug Administration. Warning Letter #716822 to DirectMeds. September 9, 2025.
17. U.S. Food and Drug Administration. MedWatch: The FDA Safety Information and Adverse Event Reporting Program.
18. U.S. Food and Drug Administration. FDA Form 483 Frequently Asked Questions.
19. U.S. Food and Drug Administration. Warning Letter to Xcel Research LLC. December 10, 2024.
20. U.S. Food and Drug Administration. FDA approves first new molecular entity under National Priority Voucher Program.
21. U.S. Food and Drug Administration. Wegovy prescribing information. 2026.

State regulators

22. Mississippi Board of Pharmacy. "Compounded Products Due to Shortage or Due to Special Patient Needs."
23. New Jersey Division of Consumer Affairs, Board of Pharmacy. "Semaglutide Compounding Statement."
24. Ohio Board of Pharmacy. "Compounding of Glucagon-like Peptide-1 Drug Products." Updated July 17, 2025.

Independent analysis, research, and academic guidance

25. Brookings. "The Wild East of semaglutide." April 21, 2025.
26. Stanford Medicine. "Compounded GLP-1s: Why doctors worry and the FDA is cracking down." July 16, 2026.
27. Jordan B, et al. "A novel, widespread impurity in mass-compounded tirzepatide/B12 products." Expert Opinion on Drug Safety. 2026. doi:10.1080/14740338.2026.2663185. All listed authors were affiliated with Eli Lilly and Company.

Manufacturer and trade-group statements

28. Eli Lilly and Company. Open letter on tirzepatide compounded with vitamin B12. March 12, 2026.
29. Alliance for Pharmacy Compounding. Statement responding to Lilly's tirzepatide/B12 impurity claims. March 12, 2026.

Provider-stated pricing, products, and pharmacy disclosures

30. Ro. Weight Loss Program Pricing. Verified August 8, 2026.
31. Ro. Weight Loss Program and Insurance. Verified August 8, 2026.
32. Embody. Program pricing, FAQ, terms, and pharmacy-partner disclosures. Verified August 8, 2026.
33. Enhance.MD. Terms of Service. Effective August 28, 2025; verified August 8, 2026.
34. Enhance.MD. "How to Get GLP-1 Medications Without Insurance Safely and Affordably." Verified August 8, 2026.

Accreditation programs

35. Accreditation Commission for Health Care. PCAB Compounding Pharmacy Accreditation.
36. National Association of Boards of Pharmacy. Compounding Pharmacy Accreditation.